Cumulative incidence of metachronous colorectal cancer

Abstract

The incidence of metachronous colorectal cancer has most often been reported as a crude rate: second cancers/index cancers. The reported incidence varies between 0.5 percent and 3.6 percent. However, these calculations do not take into account factors such as length of survival and length of follow-up. The cumulative incidence more accurately reflects the risk for developing a metachronous cancer and was determined in a retrospective analysis of 5,476 patients who were diagnosed with colon or rectal cancer between 1965 and 1985. The cumulative probability was calculated by determining the number of patients developing a metachronous colon cancer vs. the number remaining at risk at that point in time. The calculated annual incidence for metachronous tumors was 0.35 percent per year. The cumulative incidence at 18 years was 6.3 percent. Analysis also demonstrated that metachronous cancers were diagnosed at earlier stages than were index cancers (P = 0.03). Subgroup analysis was performed on patients diagnosed with metachronous cancer before and after 1980. There was a difference in the incidence of metachronous cancers between these two groups (P = 0.04).

S3-Guidelines Colorectal Cancer 2004

“…Themenkomplex IV). [81,89,147,209,225,233,241,373,425,432,494,598]. Zum Nutzen von Nachsorgemaßnahmen bei diesem Tumor gibt es 6 randomisierte kontrollierte Studien [294,352,408,424,484,495] res-Überleben einer intensivierten Nachsorge im Vergleich zu einer "Standardnachsorge" nachweisen konnten [424,495].…”

Surveillance of patients following surgery with curative intent for colorectal cancer

“…There is evidence that high risk (Stage Ⅱ or Ⅲ) patients with imaging-detected recurrence have better survival than those who relapse and present with symptoms, even after taking lead-time bias into account, most likely due to amenability to resection [37] . Survivors of colorectal cancer are at increased risk of developing new primary tumours [38][39][40] , and surveillance results in metachronous primary cancers being diagnosed at earlier stages than index tumours, with high rates of potentially curative resection [41] . Most relapse detected by surveillance is not curable.…”

ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

“…In Northern-America and Western Europe, the standardized incidence is 24.6 and 39.1 cases/100,000/y for women and men, respectively. About half of the patients develop metastasis or recurrent disease (1). Some patients may be cured with surgery, but most of them need a chemotherapeutic treatment.…”